Core Insights - OPKO Health reported revenue of 183.6millionforthequarterendedDecember2024,reflectingayear−over−yearincreaseof0.9155.14 million by 18.35% [1] - The company achieved an EPS of 0.01,asignificantimprovementfrom−0.09 in the same quarter last year, resulting in an EPS surprise of 109.09% against the consensus estimate of -0.11[1]RevenueBreakdown−Revenuefromthetransferofintellectualpropertyandothersourceswas43.10 million, exceeding the average estimate of 14.89millionbyanalysts,markingayear−over−yearincreaseof193.237.40 million, which fell short of the average estimate of 42.96million,representingayear−over−yeardeclineof13103.10 million, slightly above the estimated $97.29 million, but showed a year-over-year decrease of 17% [4] Stock Performance - OPKO Health's shares have returned +10.7% over the past month, contrasting with a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]